Our Story
SL BIO Co., Ltd. (SL BIO) is focused on advancing next-generation research programs in immuno-oncology while expanding its established portfolio of non-cellular biologic materials. Our pipeline includes investigational immune cell platforms currently in preclinical development, along with a formulation-stage exosome portfolio derived from non-human sources such as plant and milk-based materials. These parallel efforts position SL BIO at the intersection of translational immunology and early stage regenerative science. In 2024, SL BIO completed a strategic capital raise and investment framework restructuring to support long-term growth across both immune-based R&D programs and non-therapeutic formulation platforms.
Innovation
SL BIO is innovating across two complementary research areas: immuno-oncology and regenerative formulation science. In oncology, the company is advancing investigational cell-based platforms that explore the potential of immune cell redirection for use in translational cancer research.
In parallel, SL BIO has developed a formulation-stage exosome platform sourced from non-human origins, including plant and bovine milk. These cell-free vesicles are being studied for their compatibility in cosmetic and topical systems focused on maintaining scalp and skin condition.
Together, these development paths reflect SL BIO’s commitment to exploring scalable, research-driven solutions across both immune-based discovery and non- cellular formulation innovation.
Research & Development
SL BIO’s research and development efforts focus on two core areas: immune cell redirection for oncology research and the development of non-cellular biologics for topical formulation science.
In oncology, SL BIO is exploring the use of immune-responsive cell platforms to investigate tumor-associated targeting in preclinical systems. These efforts aim to support translaonal research into cell-based immune engagement strategies.
For non-cellular applications, SL BIO has established a proprietary exosome platform derived from plant and milk sources. These naturally sourced, cell-free vesicles are under evaluation for their compatibility in skin and scalp care formulations designed to support appearance, hydration, and barrier conditioning.
Through these parallel R&D pathways, SL BIO is advancing investigational platforms that support innovation in both immune-driven discovery and cosmetic formulation development.
Our Vision & Commitment
SL BIO’s vision is to contribute to the future of healthcare by advancing research- driven innovation in immune cell science and non-cellular biologics. Our work is focused on supporting the development of preclinical platforms both cell-based and cell-free that are designed for investigational use across oncology and regenerative research applications.
We are committed to ethical research, scientific transparency, and responsible innovation. Our development efforts include immune cell redirection platforms and exosome-based formulation systems sourced from plant and milk-derived materials, with applications in both cancer research and topical formulation science.
Through sustained investment in early-stage R&D and collaborative partnerships, SL BIO aims to deliver high-integrity innovation that aligns with long-term goals in translational research and global scientific advancement.
